Drug Trial Radar · NCT03699956
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Dec 24, 2018
Primary completion
Aug 11, 2022
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Conditions
- Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP DeviceCombination product
RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
Cisplatin/carboplatin plus etoposideDrug
Standard of care platinum doublet chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: Estimated up to 12 Months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Centura Health Research Center
Denver, Colorado
Mid Florida Hematology and Oncology Center
Orange City, Florida
AdventHealth Hematology and Oncology
Orlando, Florida
H. Lee Moffitt Cancer Center & Research Institute, Inc.
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
Cotton O'Neil Clinical Research Center.Hematology & Oncology
Topeka, Kansas
The University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky
University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center
Baltimore, Maryland
University of Mississippi Medical Center
Jackson, Mississippi
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Stephenson Cancer Center
Oklahoma City, Oklahoma
Tennessee Cancer Specialists
Knoxville, Tennessee
Millennium Oncology
Houston, Texas
HOPE Cancer Center of East Texas
Tyler, Texas
Utah Cancer Specialist
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.